大剂量他汀类药物临床应用的理性思考

[1] Statins,risk of diabetes,and implications on outcomes in the general population. Wang KL,Liu CJ,Chao TF,et al. Journal of the American College of Cardiology . 2012

[2] Intensive lowering of LDL cholesterol with80mg versus20mg simvastatin daily in12,064survivors of myocardial infarction:a double-blind randomised trial. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)Collaborative Group. The Lancet . 2010

[3] Statins, Risk of Diabetes, and Implications on Outcomes in the General Population[J] . Kang-Ling Wang,Chia-Jen Liu,Tze-Fan Chao,Chi-Ming Huang,Cheng-Hsueh Wu,Su-Jung Chen,Tzeng-Ji Chen,Shing-Jong Lin,Chern-En Chiang. &nbspJournal of the American College of Cardiology . 2012 (14)

[4] The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J] . Cholesterol Treatment Trialists’ (CTT) Collaborators. &nbspThe Lancet . 2012 (9841)

[5] Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies[J] . Giuseppe Patti,Christopher P. Cannon,Sabina A. Murphy,Simona Mega,Vincenzo Pasceri,Carlo Briguori,Antonio Colombo,Kyeong Ho Yun,Myung Ho Jeong,Jung-Sun Kim,Donghoon Choi,Huseyin Bozbas,Masayoshi Kinoshita,Keiichi Fukuda,Xin-Wei Jia,Hidehiko Hara,Serkan Cay,Germano Di Sciascio. &nbspCirculation . 2011 (15)

[6] Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials[J] . Naveed Sattar,David Preiss,Heather M Murray,Paul Welsh,Brendan M Buckley,Anton JM de Craen,Sreenivasa Rao Kondapally Seshasai,John J McMurray,Dilys J Freeman,J Wouter Jukema,Peter W Macfarlane,Chris J Packard,David J Stott,Rudi G Westendorp,James Shepherd,Barry R Davis,Sara L Pressel,Roberto Marchioli,Rosa Maria Marfisi,Aldo P Maggioni,Luigi Tavazzi,Gianni Tognoni,John Kjekshus,Terje R Pedersen,

[7] Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study[J] . Vincenzo Pasceri,Giuseppe Patti,Annunziata Nusca,Christian Pristipino,Giuseppe Richichi,Germano Di Sciascio. &nbspCirculation . 2004 (6)

[8] Clinical benefit of statinpretreatment in patients undergoing percutaneous coronary interven-tion:a collaborative patient-level meta-analysis of 13 randomizedstudies. Patti G,Cannon CP,Murphy SA,et al. Circulation . 2011

[9] Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. De Lemos JA,Blazing MA,Wiviott SD,et al. Journal of the American Medical Association, The . 2004

[10] Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Pasceri V,Patti G,Nusca A,et al. Circulation . 2004

[1] Statins,risk of diabetes,and implications on outcomes in the general population. Wang KL,Liu CJ,Chao TF,et al. Journal of the American College of Cardiology . 2012

[2] Intensive lowering of LDL cholesterol with80mg versus20mg simvastatin daily in12,064survivors of myocardial infarction:a double-blind randomised trial. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH)Collaborative Group. The Lancet . 2010

[3] Statins, Risk of Diabetes, and Implications on Outcomes in the General Population[J] . Kang-Ling Wang,Chia-Jen Liu,Tze-Fan Chao,Chi-Ming Huang,Cheng-Hsueh Wu,Su-Jung Chen,Tzeng-Ji Chen,Shing-Jong Lin,Chern-En Chiang. &nbspJournal of the American College of Cardiology . 2012 (14)

[4] The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials[J] . Cholesterol Treatment Trialists’ (CTT) Collaborators. &nbspThe Lancet . 2012 (9841)

[5] Clinical Benefit of Statin Pretreatment in Patients Undergoing Percutaneous Coronary Intervention: A Collaborative Patient-Level Meta-Analysis of 13 Randomized Studies[J] . Giuseppe Patti,Christopher P. Cannon,Sabina A. Murphy,Simona Mega,Vincenzo Pasceri,Carlo Briguori,Antonio Colombo,Kyeong Ho Yun,Myung Ho Jeong,Jung-Sun Kim,Donghoon Choi,Huseyin Bozbas,Masayoshi Kinoshita,Keiichi Fukuda,Xin-Wei Jia,Hidehiko Hara,Serkan Cay,Germano Di Sciascio. &nbspCirculation . 2011 (15)

[6] Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials[J] . Naveed Sattar,David Preiss,Heather M Murray,Paul Welsh,Brendan M Buckley,Anton JM de Craen,Sreenivasa Rao Kondapally Seshasai,John J McMurray,Dilys J Freeman,J Wouter Jukema,Peter W Macfarlane,Chris J Packard,David J Stott,Rudi G Westendorp,James Shepherd,Barry R Davis,Sara L Pressel,Roberto Marchioli,Rosa Maria Marfisi,Aldo P Maggioni,Luigi Tavazzi,Gianni Tognoni,John Kjekshus,Terje R Pedersen,

[7] Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study[J] . Vincenzo Pasceri,Giuseppe Patti,Annunziata Nusca,Christian Pristipino,Giuseppe Richichi,Germano Di Sciascio. &nbspCirculation . 2004 (6)

[8] Clinical benefit of statinpretreatment in patients undergoing percutaneous coronary interven-tion:a collaborative patient-level meta-analysis of 13 randomizedstudies. Patti G,Cannon CP,Murphy SA,et al. Circulation . 2011

[9] Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. De Lemos JA,Blazing MA,Wiviott SD,et al. Journal of the American Medical Association, The . 2004

[10] Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study. Pasceri V,Patti G,Nusca A,et al. Circulation . 2004